Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an update.
Duality Biotherapeutics, Inc. has announced its proposal to adopt the 2025 Share Scheme, which aims to attract and retain key participants crucial to the company’s long-term growth. The scheme is designed to recognize and reward contributions, providing participants with opportunities to acquire proprietary interests in the company, thereby enhancing its overall value. The adoption of this scheme is contingent upon shareholder approval at an extraordinary general meeting and the subsequent approval from the Listing Committee of The Stock Exchange of Hong Kong Limited.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a company incorporated under the laws of the Cayman Islands, focusing on the biotherapeutics industry. It operates with a group of subsidiaries and is listed on The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 1,365,857
Technical Sentiment Signal: Hold
Current Market Cap: HK$28.99B
For an in-depth examination of 9606 stock, go to TipRanks’ Overview page.